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New Approaches to Correcting Metabolic 
Errors in Tay-Sachs
Katherine Stefanski
Tay-Sachs Disease (TSD) is a neurodegenerative disorder categorized as both a gangliosidosis and 
a lysosomal storage disease. Tay-Sachs is caused by a deficiency in the enzyme β-hexosaminidase 
A (Hex A). There is no current remedy available for TSD. However, there have been promising 
studies and breakthroughs on the use of gene therapy to cure Tay-Sachs, and these studies will be 
discussed in this review article. Initial progress was made using a cell line model for TSD which 
led to subsequent studies in HEXA null knock-out mice and mice with Sandhoff disease (a related 
disease involving the same enzyme). Eventually, researchers were able to transduce the brain of 
Sandhoff mice correcting the diseases neurological symptoms. Most recently, felines with Sandhoff 
disease were also successfully treated with gene therapy. Advances made in lifespan, quality of life, 
and relative safety of the treatment in animal models implies a readiness for human trials. .
Abstract




Tay-Sachs disease (TSD), named for the two physicians who first described it, was discovered by Warren Tay, a British ophthalmologist, and Bernard Sachs, a 
neurologist from New York City. The disease presents beginning around six months of age 
with early blindness, severe mental retardation, paralysis, and in most cases death early in 
childhood before four years of age. It is most commonly seen in children of Eastern Eu-
ropean Ashkenazi Jewish descent as well as some French Canadian and Louisiana Cajun 
populations.1 TSD is an autosomal recessive disorder caused by a mutation in the gene that 
encodes for the lysosomal enzyme β-hexosaminidase A (Hex A), HEXA.2 
Metabolic Basis of Tay-Sachs
TSD is classified as both a gangliosidosis and a lysosomal storage disease.2,3 Ganglio-
sides are the principal glycolipid comprising neuronal plasma membranes. Their surface 
patterns are created and broken down by various biosynthetic and catabolic pathways. In-
herited defects in the catabolic pathways are known to exist in humans. When being re-
cycled, gangliosides are endocytosed and degraded by lysosomes. Defects in different gan-
glioside hydrolases such as β-galactosidase, β-hexosaminidase and GM2- activator protein 
(GM2) cause different forms of gangliosidoses. An inherited deficiency in Hex A, which 
leads to a ganglioside build-up in the patient, is the underlying cause of TSD, a diagnosis 
of which is confirmed through blood tests for Hex A levels.1,3
The specific ganglioside that builds up in TSD sufferers is GM2. GM2 is the target 
of lysosomal enzyme Hex A. β-hexosaminidase A is a heterodimer of α and β subunits 
encoded for by the genes HEXA and HEXB respectively. In TSD it is the HEXA gene 
that is mutated causing the deficiency in Hex A.2 The most common mutation, a 4-base 
pair insertion, causes the mRNA transcript to be unstable despite normal transcription.4 
However, other mutations also may cause the protein to be misfolded in the endoplasmic 
reticulum. This prevents the enzyme from being transported to the lysosome. In the lyso-
some, without Hex A, GM2 cannot be broken down (Fig. 1). Hex A is responsible for the 
cleaving of N-acetylgalactosamine from GM2 ganglioside. Without a means to metabolize 
GM2, it builds up in the cell and disrupts normal cellular function and eventually leads to 
cell death (Fig. 2). Martino et al. clarified the direct link between the lack of Hex A and the 
build-up of its substrates.5 The related disorder, Sandhoff disease, is caused by a mutation 
in HEXB which encodes for the β subunit of Hex A. Its symptoms are clinically indistin-
guishable from TSD.5 Since they involve the exact same enzyme complex, the two diseases 
are often studied side-by-side using animal models with Sandhoff disease.
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Figure 1. Diagram showing a comparison of a healthy ganglion cell and one affected by 
Tay-Sachs disease. In the healthy cell β-hexosaminidase A (Hex A) is transported from 
the Golgi apparatus to the lysosome (shown in white) where it breaks down ganglioside 
GM2 (GM2) the products of which are metabolized to ceramide. In the cell affected by 
Tay-Sachs disease Hex A is either not made or is misfolded which causes it to not be 
transported to the lysosome (shown in gray). In the absence of Hex A, GM2 accumulates 
(shown in stripes) and disrupts normal cellular function.
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Figure 2. Metabolic pathways involved in Tay-Sachs disease and Sandhoff disease. Gan-
glion cells metabolize gangliosides (GM1, GM2, and GM3) and globosides using enzymes 
that cleave off various groups from ceramide.  A mutated α subunit Hex A causes Tay-Sachs 
disease, while a mutated of β subunit of Hex A causes the related disease, Sandhoff disease.
Current Management
No cure exists for humans with Tay-Sachs disease. Currently, the best method of pre-
vention is carrier screening. Between 1969 and 1998 1.331 million young adults volun-
teered for the Tay-Sachs carrier detection test worldwide. During that time period, the 
number of cases of individuals diagnosed with TSD per year dropped from 50-60 to ap-
proximately 2-6 in the US and Canada.6,7
Early attempts at intravenous enzyme replacement using purified human Hex A to 
treat TSD and Sandhoff disease were found to be ineffective.8 Intracranial fusions and bone 
marrow transplants also proved to be clinically ineffective. Meanwhile, families and clini-
cians can only manage the symptoms of the disease. Palliative care includes feeding tubes, 
range-of-motions exercises and medications for seizures to comfort the patient and ease 
suffering before death.9 
Breakthroughs in Gene Therapy 
First Steps
In their paper published in 1996, Akli et al. describe successfully restoring Hex A 
activity in fibroblasts (a type of cell commonly found in connective tissue) taken from a 
human subject suffering from TSD using adenoviral vector-mediated gene transfer.10 The 
fibroblasts expressing the recombinant α subunit showed an enzyme activity of 40-80% of 
normal. These corrected cells secreted up to 25 times more Hex A than the control TSD 
fibroblasts and showed a normalized degradation of GM2. 
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Mouse Models
Inspired by this accomplishment, members of the same research team (Guidotti et al.) 
published a paper in 1999 describing their use of gene therapy to treat TSD in Hex A null 
mice.11 Their goal was to find an in vivo strategy that resulted in the highest Hex A activ-
ity in the greatest number of tissues. It should be noted that they used adenoviral vectors 
carrying human Hex genes. Using vectors carrying the α subunit gene alone brought about 
only partial correction of Hex A activity. Intravenous co-administration of vectors coding 
for both α and β subunits of Hex A demonstrated a more successful correction of Hex A 
levels. The use of both subunits led to high levels of Hex A being secreted by peripheral tis-
sues (heart, liver, spleen, skeletal muscle, and kidney) indicating that exogenous α subunits 
were unable to dimerize with the low amounts of endogenous β subunits. 
The authors contended that while gene therapy would ideally require the transduction 
of the majority of cells in an organism, this was an unrealistic goal. Therefore, it was their 
objective to transduce a large number of cells in a large organ causing them to produce 
and secrete Hex A into the bloodstream in large enough quantities to be taken up by 
non-transduced cells.  They found that injecting the liver brought about transduction of 
peripheral tissues while injecting other tissue, such as skeletal muscle, did not. The obvious 
drawback of this study is that Hex A deficiency was not corrected in the brain. Intravenous 
adenovirus gene transfer does not transduce the brain nor does the secreted enzyme from 
peripheral tissues cross the blood-brain barrier. 
Treating the Brain and Body
In their 2006 paper, Cachon-Gonzalez et al. describe their method of transducing 
neuronal cells with Hex A α and β subunit genes.12 They used HEXB null mice with Sand-
hoff disease and treated them with stereotaxic intracranial inoculation of recombinant ade-
no-associated viral (rAAV) vectors encoding both subunits of Hex A, including an HIV tat 
sequence which greatly increases gene expression and distribution. The authors were able 
to show that rAAV transduces neurons and promotes the secretion of active Hex A after a 
single injection. Their evidence indicated a widespread delivery of the enzyme to both the 
brain and spinal cord. The mice in their study survived for over one year while the untreated 
mice died before 20 weeks of age. Initially, the motor ability of the treated Sandhoff mice 
was indistinguishable from the wild-type mice while the untreated mice showed a drastic 
decline in motor function. 
In their follow-up study published in 2012, Cachon-Gonzalez et al. used a modified 
treatment technique yielding more significant results.13 Again, using rAAV vectors carrying 
both human Hex A subunits, Sandhoff mice were given intracranial co-injections into the 
cerebrospinal fluid space and intraparenchymal administration at a few strategic sites. Mice 
were injected at one month and survived for an unprecedented two years, and the classical 
manifestations of the disease were completely resolved.   
An earlier study using Neimann-Pick disease supports Cachon-Gonzalez’s contention 
that multiple injection sites yield more clinically effective results.14 Niemann-Pick disease 
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is another lysosomal storage disease similar to TSD. Passini et al. (2007) used mice with 
this disorder to further investigate gene therapy on lysosomal storage diseases.14 Using 
rAAV vectors, they were able to reverse the pathology of the treated mice with both visceral 
and brain injections. These mice showed superior weight gain and recovery of motor and 
cognitive functions, when compared to mice treated with either brain or visceral injection 
alone. The authors assert that this affirms the benefits of multi-site gene delivery strategies 
in diseases that affect the whole body. 
Feline Experiments
Working from the successes of the trials with mice, Bradbury et al. conducted stud-
ies using felines with Sandhoff disease.15 A cat’s brain is more than 50 times larger than a 
mouse’s, making it a better analog for the treatment of human brains. The researchers first 
attempted treating two cats with the same vectors used in the mouse studies. These treated 
cats lived for 7.0 and 8.2 months while untreated cats survived for just 4.1 months. While 
the two treated cats did show an increase in lifespan, they also showed a pronounced im-
mune response to AAV vector and the human Hex A. Researchers then used AAVrh8 
vectors with feline Hex A cDNAs. Three cats were injected with these vectors and survived 
for an average of 10.4 months. They also found that when phenotypically normal cats were 
injected with the AAVrh8 vector and examined after 21 months, they showed no sign of 
vector toxicity.15 
The cats receiving the AAVrh8 vectors were injected twice. While they showed an 
increase in lifespan and quality of life, and Hex A activity was increased in most regions of 
the brain, its activity was minimal in the temporal lobe and cerebellum. Given that the cat 
brain is about 20 times smaller than a human infant’s, the authors suggest that additional 
injection sites would provide better therapeutic benefits.15 This assertion accords with the 
findings of Passini et al. in Neimann-Pick mice. 
Jacob Sheep as a Potential Model
A line of European Jacob Sheep with a disease similar to TSD has been discovered. 
The afflicted juveniles show a similar ataxia and early death as other Tay-Sachs animal 
models.17 These sheep exhibit a lack of Hex A activity and a missense mutation in the 
HEXA gene has been located.18 Given that a sheep’s brain is even more similar in size and 
volume to a human brain these sheep are a promising model for the next steps of Tay-Sachs 
gene therapy research.  Researchers have an opportunity with these sheep to further refine 
injection strategies before human testing.
Conclusions
Human trials are the obvious next step in researching a gene therapy treatment for 
Tay-Sachs. Promising results have been seen in experiments described above using gene 
transfer in human Tay-Sachs cells.12 The results of studies on mice have shown promise in 
the correction of Hex A expression in the brain and body tissues of mice and felines.13,14 
Many advances have been made in the understanding of implementing gene therapy, spe-
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cifically in treatment of gangliosidoses. An understanding of the need to transfer the genes 
for both subunits of Hex A has been established. Viral-based gene therapy, however, has 
not been without its problems.  Host-induced antibodies and inflammation can limit the 
use of viral vectors. More specifically, antibodies to adenoviruses exist in most people, which 
limit reinjections. To combat this, second generation adenoviral vectors have been created 
with fewer viral genes, which reduce the host’s immune response. Vector-related toxicity 
and immunogenicity related to the remaining viral genes can still present complications.16 
Nevertheless, improvements in the understanding of which vectors and techniques show 
success in transducing neural cells of the brain in TSD and Sandhoff models have been 
made. Additionally, these vectors and injection techniques have also not been shown to 
have deleterious side effects in asymptomatic animal models. Given the progresses made 
in safety, any remaining risks of gene therapy are outweighed by the severity of TSD. Hu-
man trials will hopefully demonstrate a reversal of symptoms in patients giving them a 
more normal lifespan. In fact, the Tay-Sachs Gene Therapy Consortium, a collaborative of 
researchers from Auburn University, Boston College, Harvard University/Massachusetts 
General Hospital, and Cambridge University are attempting to begin these trials by the 
end of 2014.19 
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